These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
549 related articles for article (PubMed ID: 30347480)
1. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Tanios GE; Doley PB; Munker R Eur J Haematol; 2019 Feb; 102(2):157-162. PubMed ID: 30347480 [TBL] [Abstract][Full Text] [Related]
5. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report. Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P Front Immunol; 2024; 15():1342845. PubMed ID: 38571955 [TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
7. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Cortellini A; Buti S; Agostinelli V; Bersanelli M Semin Oncol; 2019; 46(4-5):362-371. PubMed ID: 31727344 [TBL] [Abstract][Full Text] [Related]
8. Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin. Algaze SD; Park W; Harrington TJ; Mudad R BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29523604 [TBL] [Abstract][Full Text] [Related]
9. Management of immune related adverse events induced by immune checkpoint inhibition. Teufel A; Zhan T; Härtel N; Bornschein J; Ebert MP; Schulte N Cancer Lett; 2019 Aug; 456():80-87. PubMed ID: 31051213 [TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. Ali AK; Watson DE Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039 [TBL] [Abstract][Full Text] [Related]
12. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system. Aggarwal P Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310 [No Abstract] [Full Text] [Related]
13. [Management of Toxicities of Immune Checkpoint Inhibitors]. Horio Y Gan To Kagaku Ryoho; 2017 Mar; 44(3):185-190. PubMed ID: 28292987 [TBL] [Abstract][Full Text] [Related]
14. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. Brahmer JR; Lacchetti C; Thompson JA J Oncol Pract; 2018 Apr; 14(4):247-249. PubMed ID: 29517954 [No Abstract] [Full Text] [Related]
15. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. Safa H; Johnson DH; Trinh VA; Rodgers TE; Lin H; Suarez-Almazor ME; Fa'ak F; Saberian C; Yee C; Davies MA; Tummala S; Woodman K; Abdel-Wahab N; Diab A J Immunother Cancer; 2019 Nov; 7(1):319. PubMed ID: 31753014 [TBL] [Abstract][Full Text] [Related]
16. Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy. Palla AR; Kennedy D; Mosharraf H; Doll D Case Rep Oncol; 2016; 9(3):691-697. PubMed ID: 27920704 [TBL] [Abstract][Full Text] [Related]